The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection

Gut

Volumn 67, Issue 3, 2018, Pages 553-561

  Mahale, Parag ^a,b,c   Engels, Eric A ^a   Li, Ruosha ^b   Torres, Harrys A ^d   Hwang, Lu Yu ^b   Brown, Eric L ^b   Kramer, Jennifer R ^b,c,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

antiviral therapy; extrahepatic manifestations; Hepatitis C virus; sustained virological response

Indexed keywords

INTERFERON; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CRYOGLOBULINEMIA; DIABETES MELLITUS; FEMALE; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; ISCHEMIC HEART DISEASE; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SUSTAINED VIROLOGIC RESPONSE; BLOOD; CHRONIC HEPATITIS C; CORONARY ARTERY DISEASE; FOLLOW UP; GOVERNMENT; INCIDENCE; REGISTER; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CORONARY DISEASE; CRYOGLOBULINEMIA; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LICHEN PLANUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PORPHYRIA CUTANEA TARDA; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; STROKE; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; YOUNG ADULT;

EID: 85026636258     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-313983     Document Type: Article

References (53)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.
3. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 2005;41:790-800.
4. Negro F, Forton D, Craxì A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149:1345-60.
5. Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 2016;15:1145-60.
6. Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008;72:1960-5.
7. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009;49:225-32.
8. Hsu YH, Muo CH, Liu CY, et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: A 9-year population-based cohort study. J Hepatol 2015;62:519-25.
9. Lee MH, Yang HI, Wang CH, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010;41:2894-900.
10. Liao CC, Su TC, Sung FC, et al. Does hepatitis C virus infection increase risk for stroke A population-based cohort study. PLoS One 2012;7:e31527.
11. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38:50-6.
12. Montenegro L, De Michina A, Misciagna G, et al. Virus C hepatitis and type 2 diabetes: A cohort study in Southern Italy. Am J Gastroenterol 2013;108:1108-11.
13. Vassalle C, Masini S, Bianchi F, et al. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004;90:565-6.
14. Wang CS, Wang ST, Yao WJ, et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007;166:196-203.
15. AA SLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.
16. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
17. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and Ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
18. Vander Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
19. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
20. Nahon P, Bourcier V, Layese R, et al. Eradication of Hepatitis C virus infection in patients with Cirrhosis reduces risk of liver and Non-Liver complications. Gastroenterology 2017;152:142-56.
21. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-6.
22. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-44.
23. Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: A population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013;38:415-23.
24. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:495-503.
25. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034-41.
26. Agnello V, Chung RT , Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5.
27. Arcaini L, Bruno R. Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol 2010;5:74-81.
28. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi. Ann Oncol 2014;25:1404-10.
29. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
30. Backus LI, Gavrilov S, Loomis TP, et al. Clinical case registries: Simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009;16:775-83.
31. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47.
32. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5.
33. Zeuzem S, Heathcote EJ, Shiffman ML, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003;39:106-11.
34. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to multiple testing. Journal of the Royal Statistical Society Series B 1995;57:289-300.
35. Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016;150:1599-608.
36. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
37. Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferonfree direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
38. Toyoda H, Tada T, Takaguchi K, et al. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat 2016.
39. De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-8.
40. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-7.
41. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013;369:1035-45.
42. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. effect of alpha-interferon therapy. Kidney Int 1994;46:1700-4.
43. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
44. Shengyuan L, Songpo Y, Wen W, et al. Hepatitis C virus and lichen planus: A reciprocal association determined by a meta-analysis. Arch Dermatol 2009;145:1040-7.
45. G isbert JP, Garciá-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in Porphyria cutanea tarda: Systematic review and meta-analysis. J Hepatol 2003;39:620-7.
46. Berk DR, Mallory SB, Keeffe EB, et al. Dermatologic disorders associated with chronic hepatitis C: Effect of interferon therapy. Clin Gastroenterol Hepatol 2007;5:142-51.
47. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, et al. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993;104:903-5.
48. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592-9.
49. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol 2008;49:831-44.
50. Nakamura K, Kawasaki E, Imagawa A, et al. Type 1 diabetes and interferon therapy: A nationwide survey in Japan. Diabetes Care 2011;34:2084-9.
51. Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. role of HCV and HCV-related steatosis. Atherosclerosis 2012;221:496-502.
52. Hansson GK, Inflammation HGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
53. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573-7.